Global Drug Surveillance: The WHO Programme for International Drug Monitoring

Pharmacoepidemiology, Fourth Edition

Volumn , Issue , 2007, Pages 161-183

  Edwards, I Ralph ^a   Olsson, Sten ^a   Lindquist, Marie ^a   Hugman, Bruce ^a,b  

^a UPPSALA MONITORING CENTRE   (Sweden)

^b NARESUAN UNIVERSITY   (Thailand)

Author keywords

CIOMS II safety updates and ICH countries; Data mining approaches to signal detection; Data mining knowledge finding; European Union (EU) pharmacovigilance system; Global drug surveillance; Good communication practices and drug safety improvement; Spontaneous reporting systems and new drug safety signal detection; Suspected adverse drug reactions (ADRs); WHO Collaborating Centre for Uppsala International Drug Monitoring; WHO Drug Information

Indexed keywords

EID: 84889324173     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470059876.ch10     Document Type: Chapter

References (91)

1. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961;2:1358.
2. Finney DJ, Sadusk J. The scientific group on monitoring adverse drug reactions report to the Director General, report PA/d.65 Geneva: World Health Organization, 1964.
3. Finney DJ. The design and logic of a monitor of drug use. J Chronic Dis 1965;18:77-98.
4. Finney DJ. Systematic signalling of adverse reactions to drugs. Methods Inf Med 1974;13:1-10.
5. WHO. The Importance of Pharmacovigilance. Safety Monitoring of Medicinal Products. Geneva: World Health Organization, 2002.
6. Amery W. Signal generation from spontaneous adverse event reports. Pharmacoepidemiol Drug Saf 1999;8:147-50.
7. EMEA. Note for Guidance on Procedure for Competent Authorities on the Undertaking of Pharmacovigilance Activities. London: The European Agency for the Evaluation of Medicinal Products, 1999.
8. Meyboom RH, Egberts AC, Edwards IR, Hekster YA, de Koning FH, Gribnau FW. Principles of signal detection in pharmacovigilance. Drug Saf 1997;16:355-65.
9. Olsson S, ed. National Pharmacovigilance Systems, 2nd edn. Uppsala: Uppsala Monitoring Centre, 1997.
10. UMC. Safety Monitoring of Medicinal Products. Uppsala: Uppsala Monitoring Centre, 2000.
11. CIOMS. International Reporting of Adverse Drug Reactions. Geneva: CIOMS, 1990.
12. CIOMS. Current Challenges in Pharmacovigilance: Pragmatic Approaches. Geneva: CIOMS, 2001.
13. Edwards IR, Lindquist M, Wiholm BE, Napke E. Quality criteria for early signals of possible adverse drug reactions. Lancet 1990;336:156-8.
14. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11:272-6.
15. Benichou C, Solal-Celigny P. Standardization of definitions and criteria for causality assessment of adverse drug reactions. Drug-induced blood cytopenias: report of an international consensus meeting. Nouv Rev Fr Hematol 1991;33:257-62.
16. CIOMS. Basic requirements for the use of terms for reporting of drug reactions. Pharmacoepidemiol Drug Saf 1992;1:39-45.
17. CIOMS. Basic requirements for the use of terms for reporting of drug reactions (II). Pharmacoepidemiol Drug Saf 1992;1:133-7.
18. CIOMS. Harmonizing the use of adverse drug reactions and minimum requirements for their use: respiratory disorders and skin disorders. Pharmacoepidemiol Drug Saf 1997;6:115-27.
19. CIOMS. Basic requirements for the use of terms for reporting adverse drug reactions (VIII): renal and urinary system disorders. Pharmacoepidemiol Drug Saf 1997;6:203-11.
20. Meyboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf 1997;17:374-89.
21. Herman RL. Drug-event association: perspectives, methods and uses. Drug Inf J 1984;18:195-337.
22. Venulet J, Berneker G-C, Ciucci AG, eds, Assessing Causes of Adverse Drug Reactions. London: Academic Press, 1982.
23. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 1977;21:247-54.
24. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA 1979;242:623-32.
25. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
26. Louik C, Lacouture PG, Mitchell AA, Kauffman R, Lovejoy FH, Jr, Yaffe SJ et al. A study of adverse reaction algorithms in a drug surveillance program. Clin Pharmacol Ther 1985;38:183-7.
27. Pere JC, Begaud B, Haramburu F, Albin H. Computerized comparison of six adverse drug reaction assessment procedures. Clin Pharmacol Ther 1986;40:451-61.
28. Moore N, Biour M, Paux G, Loupi E, Begaud B, Boismare F et al. Adverse drug reaction monitoring: doing it the French way. Lancet 1985;2:1056-8.
29. Biriell C, Edwards IR. Reasons for reporting adverse drug reactions-some thoughts based on an international review. Pharmacoepidemiol Drug Saf 1997;6:21-6.
30. Weber JCP. Epidemiology in the United Kingdom of adverse drug reactions from nonsteroidal anti-inflammatory drugs. In: Rainsford KD, Velo GP, eds, Side Effects of Anti-Inflammatory Drugs. Lancaster: MTP Press, 1986; pp. 27-36.
31. Holmberg L, Boman G, Bottiger LE, Eriksson B, Spross R, Wessling A. Adverse reactions to nitrofurantoin. Analysis of 921 reports. Am J Med 1980;69:733-8.
32. Wiholm B-E, Myrhed M, Ekman E. Trends and patterns in adverse drug reactions to nonsteroidal anti-inflammatory drugs reported in Sweden. In: Rainsford KD, Velo GP, eds, Side Effects of Anti-Inflammatory Drugs. Lancaster: MTP Press, 1986; pp. 55-62.
33. Stricker BH, Tijssen JG. Serum sickness-like reactions to cefaclor. J Clin Epidemiol 1992;45:1177-84.
34. Moore N, Kreft-Jais C, Haramburu F, Noblet C, Andrejak M, Ollagnier M et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol 1997;44:513-18.
35. Egberts AC, Meyboom RH, van Puijenbroek EP. Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf 2002;25:453-8.
36. Edwards IR. Adverse drug reactions: finding the needle in the haystack. BMJ 1997;315:500.
37. Bate A. The Use of a Bayesian Confidence Propagation Neural Network in Pharmacovigilance. Umeå: Umeå University, 2003.
38. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998;54:315-21.
39. Lindquist M. Seeing and Observing in International Pharmacovigilance-Achievements and Prospects in Worldwide Drug Safety. Nijmegen: University of Nijmegen, 2003.
40. Lindquist M, Edwards IR, Ståhl M, Brown EG, Bate A, Kiuru A. The effect of different strategies of signal finding in WHO international ADR data. Proceedings of ISoP Conference 2001, abstract L14.
41. Bate A, Orre R, Lindquist M, Edwards IR. Explanation of data mining methods. Available at: http://www.bmj.bmjjournals.com/cgi/content/full/322/7296/1207/DC1/.
42. Bate AJ, Lindquist M, Edwards IR, Orre R. Understanding quantitative signal detection methods in spontaneously reported data. Pharmacoepidemiol Drug Saf 2002;11 (suppl 1): 214-15.
43. Lindquist M, Stahl M, Bate A, Edwards IR, Meyboom RH. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf 2000;23:533-42.
44. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001;10:483-6.
45. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002;11:3-10.
46. van Puijenbroek EP, van Grootheest K, Diemont WL, Leufkens HG, Egberts AC. Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. Br J Clin Pharmacol 2001;52:579-86.
47. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat 1999;53:177-90.
48. Edwards IR, Olsson, S. The WHO International Drug Monitoring Programme-vision and goals of the Uppsala Monitoring Centre. In: Aronson JK, ed., Side Effects of Drugs, Annual 26. Amsterdam: Elsevier Science, 2003; pp. 548-57.
49. Meyboom RHB. Good practice in the postmarketing surveillance of medicines. Pharm World Sci 1997;4:19.
50. Meyboom RHB. The case for good pharmacovigilance practice. Pharmacoepidemiol Drug Saf 2000;9:335-6.
51. CIOMS. Harmonization of Data Fields for Electronic Transmission of Case-Report Information Internationally, public report. Geneva: CIOMS, 1995.
52. CIOMS. International Reporting of Periodic Drug Safety Update Summaries. Geneva: CIOMS, 1992.
53. Wood KL, Wood SM. The new international medical terminology for regulatory activities: a tool to improve the utilisation of regulatory data and to support its communication within and between organisations. In: Mitchard M, ed., Electronic Communication Technologies: A Practical Guide for Healthcare Manufacturers. Buffalo, NY: Interpharm Press, 1998; pp. 299-331.
54. Venning GR. Identification of adverse reactions to new drugs II. How were 18 important adverse reactions discovered and with what delay? BMJ 1983;286:289-92.
55. Wiholm B-E, Lindquist M. The detection and evaluation of drug induced agranulocytosis by spontaneous reports. Abstract. In: III World Conference on Clinical Pharmacology and Therapeutics, Stockholm, 1986.
56. Li D, Lindquist M, Edwards IR. Evaluation of early signals of drug-induced Stevens-Johnson Syndrome in the WHO ADR data base. Pharmacoepidemiol Drug Saf 1992;1:11-9.
57. Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. Adv Inflam Res 1984;6:1-7.
58. Edwards IR, Fletcher AP, Lindquist M, Pettersson M, Sanderson GH, Schou JS. The ADR Signal Analysis (ASAP), final report. EU-funded technical report, 1997.
59. Rothman KJ. Causal inference in epidemiology. In: Modern Epidemiology. Boston, MA: Little, Brown, 1986; pp. 7-21.
60. Carlson J, Wiholm B-E. Trimethoprim associated aseptic meningitis. Scand J Infect Dis 1987;19:687.
61. Stratton KR, Howe CJ, Johnston RB Jr. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. JAMA 1994;271:1602-5.
62. Nordic Council on Medicines. Drug Monitoring in the Nordic Countries. An Evaluation of Similarities and Differences, report no. 25. Uppsala: Nordic Council on Medicines, 1989.
63. Moore N, Noblet C, Kreft-Jais C, Lagier G, Ollagnier M, Imbs JL. [French pharmacovigilance database system: examples of utilisation]. Therapie 1995;50:557-62.
64. The International Agranulocytosis and Aplastic Anemia Study. Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. JAMA 1986;256:1749-57.
65. van Leeuwen R, Meyboom RH. Agranulocytosis and aprindine. Lancet 1976;2:1137.
66. Hood DA, Edwards IR. Meningococcal vaccine-do some children experience side effects? N Z Med J 1989;102:65-7.
67. Nordic Council on Medicines. Nordic Statistics on Medicines 1975-1977, part II. Uppsala: Nordic Council on Medicines, 1978.
68. Lindquist M, Pettersson M, Edwards IR, Sanderson JH, Taylor NF, Fletcher AP et al. How does cystitis affect a comparative risk profile of tiaprofenic acid with other non-steroidal antiinflammatory drugs? An international study based on spontaneous reports and drug usage data. ADR Signals Analysis Project (ASAP) team. Pharmacol Toxicol 1997;80:211-17.
69. Stahl MM, Lindquist M, Pettersson M, Edwards IR, Sanderson JH, Taylor NF et al. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol 1997;53:163-9.
70. Wiholm B-E. Spontaneous reporting of ADR. In: Detection and Prevention of Adverse Drug Reactions, Skandia International Symposia. Stockholm, Sweden: Almqvist and Wiksell, 1983; pp. 152-67.
71. Bottiger M, Romanus V, de Verdier C, Boman G. Osteitis and other complications caused by generalized BCG-itis. Experiences in Sweden. Acta Paediatr Scand 1982;71:471-8.
72. Bottiger LE, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 1980;1:1097-101.
73. Fraunfelder FT, Meyer SM, Bagby GC, Jr, Dreis MW. Hematologic reactions to carbonic anhydrase inhibitors. Am J Ophthalmol 1985;100:79-81.
74. Mortimer O, Wiholm B-E. Acetazolamid-pancytopenia: the Swedish Adverse Drug Reactions Advisory Committee 46, 1985.
75. The International Agranulocytosis and Aplastic Anemia Study. Incidence of aplastic anemia: the relevance of diagnostic criteria. Blood 1987;70:1718-21.
76. Bottiger LE, Westerholm B. Drug-induced blood dyscrasias in Sweden. BMJ 1973;3:339-43.
77. Keisu M, Ekman E, Wiholm BE. Comparing risk estimates of sulphonamide-induced agranulocytosis from the Swedish Drug Monitoring System and a case-control study. Eur J Clin Pharmacol 1992;43:211-14.
78. Asplund K, Wiholm BE, Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 1983;24:412-17.
79. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1575-82.
80. Legnani C, Cini M, Cosmi B, Poggi M, Boggian O, Palareti G. Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels. Haematologica 2004;89:1347-51.
81. Strandberg I, Boman G, Hassler L, Sjoqvist F. Acetylator phenotype in patients with hydralazine-induced lupoid syndrome. Acta Med Scand 1976;200:367-71.
82. Strom BL, West SL, Sim E, Carson JL. The epidemiology of the acute flank pain syndrome from suprofen. Clin Pharmacol Ther 1989;46:693-9.
83. CIOMS. Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals, 1st edn. Geneva: World Health Organization, 1998.
84. WHO International Drug Monitoring. Cerivastatin and Gemfibrosil, report no. 16(1). Geneva: World Health Organization, 2002.
85. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD Assignment, 3rd edn. Oslo, 2000.
86. Edwards IR. The accelerating need for pharmacovigilance. J R Coll Physicians Lond 2000;34:48-51.
87. Edwards IR, Hugman B. The challenge of effectively communicating risk-benefit information. Drug Saf 1997;17:216-27.
88. UMC. Dialogue in Pharmacovigilance-More Effective Communication. Uppsala: Uppsala Monitoring Centre, 2002.
89. UMC. Effective Communications in Pharmacovigilance. Uppsala: Uppsala Monitoring Centre, 1998.
90. UMC. Expecting the Worst-Crisis Management. Uppsala: Uppsala Monitoring Centre, 2002.
91. UMC. Viewpoint. Uppsala: Uppsala Monitoring Centre, 2002.